Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activity of gefitinib in a non-small-cell lung cancer patient with both activating and resistance EGFR mutations.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jul 2013

Morabito Alessandro, Costanzo Raffaele, Rachiglio Anna Maria, Pasquale Raffaella, Sandomenico Claudia, Franco Renato, Montanino Agnese, De Lutio Elisabetta, Rocco Gaetano, Normanno Nicola

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Large Cell
Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Gefitinib

Share to Neoplasm Metastasis

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Identifiers

PMID: 23774386
DOI: 10.1097/JTO.0b013e318286cc26

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activity of gefitinib in a non-small-cell lung cancer patient with both activating and resistance EGFR mutations.PMID 23774386Read ↗

Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.Semantic proximity Read ↗

Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial.Semantic proximity Read ↗

Gefitinib. Still no convincing results in non-small cell lung cancer.Semantic proximity Read ↗

Successful Treatment with Gefitinib in Advanced Non-Small Cell Lung Cancer after Acquired Resistance to Osimertinib.Semantic proximity Read ↗

Gefitinib for non-small-cell lung cancer treatment.Semantic proximity Read ↗

Favorable response to gefitinib treatment of lung adenocarcinoma with coexisting germline and somatic epidermal growth factor receptor mutations.Semantic proximity Read ↗

Spotlight on gefitinib in non-small-cell lung cancer.Semantic proximity Read ↗

Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation.Semantic proximity Read ↗

Geftinib.Semantic proximity Read ↗

Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer.Semantic proximity Read ↗

Primary resistance to gefitinib in a patient with lung adenocarcinoma harboring an EGFR exon 19 L747-A750>P mutation.Semantic proximity Read ↗

Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.